Visceral Pleural Invasion as a Prognostic Factor for Recurrence in Resected IB Non-small Cell Lung Cancer.
- Author:
Seok KIM
1
;
Ki Sung PARK
;
Yoon Seup KUM
;
Sub LEE
;
Chi Hoon BAE
;
Dae Sung HYUN
Author Information
1. Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Korea. kimyh67@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Neoplasm stage;
Adjuvant therapy;
Visceral pleural invasion
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Chemotherapy, Adjuvant;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Multivariate Analysis;
Proportional Hazards Models;
Recurrence;
Survival Rate
- From:The Korean Journal of Thoracic and Cardiovascular Surgery
2009;42(5):610-614
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Several trials have reported on whether adjuvant chemotherapy for resected stage IB non-small cell lung cancer is needed. The aim of our study was to investigate prognostic factors for recurrence to help identify patients who should receive adjuvant chemotherapy. MATERIAL AND METHOD: We reviewed the cases of 48 stage IB non-small cell lung cancer patients between 1997 and 2006. Disease-free survival and overall survival rates were calculated by the Kaplan-Meier method. Univariate analysis was performed with the log rank test and multivariate analysis was done using Cox's proportional hazard model. RESULT: The median follow-up time was 48 months. The overall survival rate was 55.9%, and the disease-free survival rate was 48.6%. Of 8 variables, two factors, visceral pleural invasion and lymphovascular invasion, were prognostic factors of disease-free survival (univariate analysis). Visceral pleural invasion was a significant prognostic factor in multivariate analysis, and overall survival in compared one or more variable such as visceral pleural invasion or, and lymphovascular invasion with the other variables. CONCLUSION: Visceral pleural invasion was identified as a poor prognostic factor and it may help select which patients will benefit from adjuvant chemotherapy in addition to more comprehensive follow-up.
